GSK Exercises Option to License Elsie Biotechnologies’ Discovery Platform to Find and Develop Novel Oligonucleotides
Elsie will receive a license payment and potential development and commercial milestones
Elsie’s discovery platform is an unparalleled ultra-high throughput proprietary process that allows for the complete evaluation of oligonucleotide chemical space. By applying proprietary encoding technology to oligonucleotide therapeutic candidates, all possible sequences or chemical modification patterns can be evaluated to increase activity, reduce toxicity, and improve delivery. Elsie also applies proprietary P(V) chemistry technologies, encompassing a suite of novel reagents and processes, to synthesize diverse oligonucleotide therapeutics with complete synthetic control.
Under the terms of the agreement, Elsie will receive a license payment from GSK and could receive additional development and commercial milestones on a target-by-target basis.
About Elsie Biotechnologies
Elsie Biotechnologies is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics by integrating discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery. Elsie’s discovery platform accesses the entire oligonucleotide chemistry space to optimize current modalities in gene silencing and splice switching, and applies proprietary P(V) chemistry technologies to develop novel, diverse oligonucleotide therapeutics that are designed to be more potent, safer, and easier to deliver to target tissues. To learn more, please visit elsiebio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213991639/en/
Company:
Media:
Source: